Lexpos News

Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (21/07/2023) announced the following list of price concessions for July 2023: Please note CPE is still in discussion with DHSC on several other lines of concern, including other [...]

The post July 2023 Price Concessions 3rd Update appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Atomoxetine 40mg and 60mg capsules. MSN/2023/068 Tier 2 – medium impact Date of issue 21st July 2023 Atomoxetine 40mg and 60mg capsules will be out of stock from late July 2023 until September 2023 Other strengths and formulations of atomoxetine remain [...]

The post Medicine Supply Notification: Atomoxetine 40mg and 60mg capsules appeared first on Community Pharmacy England.

Community Pharmacy England has submitted a full and detailed written response to the Health and Social Care Select Committee’s pharmacy inquiry. The Committee is expected to hold oral evidence sessions when Parliament returns in the Autumn. The commencement of this inquiry follows on from those held on other primary care sectors, including Dentistry and General [...]

The post Community Pharmacy England submits evidence to Pharmacy Inquiry appeared first on Community Pharmacy England.

Community Pharmacy England met in Leeds for a full Committee Meeting on 12th and 13th July 2023. Committee Members spent time considering urgent matters such as pharmacy pressures and the ongoing Primary Care Access Plan negotiations, with valuable input from sector polls and LPC leaders. The packed two-day meeting agenda included time to consider both [...]

The post Committee hears directly from pharmacy owners and LPCs at July Meeting appeared first on Community Pharmacy England.

CLMR number: CLMR (23)A/05 Date issued: 19 July 2023 The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company-led medicines recall for: Diltiazem HCl 2% Cream [unlicensed medicine] – Quantum Pharmaceutical MDR Number: MDR 023-07/23 Company name: Quantum Pharmaceutical Product name: Diltiazem HCl 2% Cream [unlicensed medicine] Lot number/expiry Product name Batch number [...]

The post Company Led Medicines Recall: Diltiazem HCl 2% Cream [unlicensed medicine] – Quantum Pharmaceutical appeared first on Community Pharmacy England.